GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReproCELL Incorp (FRA:6RC) » Definitions » Debt-to-Equity

ReproCELLorp (FRA:6RC) Debt-to-Equity : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is ReproCELLorp Debt-to-Equity?

ReproCELLorp's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. ReproCELLorp's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. ReproCELLorp's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €49.25 Mil. ReproCELLorp's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ReproCELLorp's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of ReproCELLorp was 0.02. The lowest was 0.01. And the median was 0.01.

FRA:6RC's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

ReproCELLorp Debt-to-Equity Historical Data

The historical data trend for ReproCELLorp's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReproCELLorp Debt-to-Equity Chart

ReproCELLorp Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.01 - -

ReproCELLorp Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ReproCELLorp's Debt-to-Equity

For the Biotechnology subindustry, ReproCELLorp's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReproCELLorp's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReproCELLorp's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ReproCELLorp's Debt-to-Equity falls into.



ReproCELLorp Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ReproCELLorp's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

ReproCELLorp's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReproCELLorp  (FRA:6RC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


ReproCELLorp Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ReproCELLorp's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


ReproCELLorp (FRA:6RC) Business Description

Traded in Other Exchanges
Address
KDX Shin-Yokohama 381 Bldg. 9F, 3-8-11, Shin-Yokohama, Kohoku-ku, Kanagawa, Yokohama, JPN, 222-0033
ReproCELL Incorp is one of the leading stem cell research company in Japan. The company provides stem cell services, predictive drug discovery services, tissue services, and molecular services.

ReproCELLorp (FRA:6RC) Headlines

No Headlines